Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma

This open-label, prospective, single-arm Phase II trial explores whether adding stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy to oligoprogressive lesions can help delay disease progression in patients with metastatic melanoma. Participants may have up to ten extracranial oligoprogressive sites, with no upper limit on the total number of metastatic lesions. The study aims to assess whether targeting these progressing sites with focused radiotherapy can extend progression-free survival in this patient population.

Trial Details

NCT ID
NCT07112170
Phase
NA
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Stereotactic Body Radiation Therapy (SBRT)
Locations (sample)
  • Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

  • Age 18 or older
  • Willing and able to provide informed consent
  • Metastatic melanoma detected on imaging and clinically confirmed.
  • Treated with first line immunotherapy or BRAF inhibitors.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →